Exploring the Potential of Cell Therapy Products Through Joint Research and Advanced Medicine

「A clinical study is under way to clarify the utility of immune-cell therapy in preemptive medicine」

「We are conducting a joint physician-initiated Phase IIb trial with Kyushu University aimed at commercializing a new regenerative medicine product, α-GalCer/DC, for the treatment of chronic heart failure. In addition to Kyushu University Hospital, patient enrollment is currently underway at the hospital of the National Cerebral and Cardiovascular Center, Juntendo University Hospital, Nara Medical University Hospital and Kobe City Medical Center General Hospital. We aim to accelerate the progress of the Phase IIb trial and commercialize α-GalCer/DC at an early stage.」

「For the next physician-initiated Phase IIb trial, the investigational product will be manufactured at our Shinagawa CPF. After establishing the manufacturing and supply system, the clinical trial notification was submitted, and the trial is currently underway.」

「We began clinical research under the joint research agreement.」

「In December 2020, we concluded a joint research agreement with Medical Corporation 滉志会 to conduct an exploratory study of changes in immune parameters before and after immune cell administration in order to appropriately evaluate the usefulness of immune cell therapy as preventive medicine, with the aim of applying it to preventive medicine.」

「In October 2019, we concluded a joint research agreement with the National Cancer Center, a National Research and Development Agency, aimed at commercializing a new cancer immunotherapy related to Heat Shock Protein105 (HSP105), one of the cancer antigen proteins. In November of the same year, we concluded a joint research agreement with Kyoto Prefectural University of Medicine, a public university corporation of Kyoto Prefecture, aimed at commercializing a specific B-cell depletion method using immune cells genetically modified with a new chimeric receptor, called a B-cell antibody receptor (BAR), for diseases caused by the production of autoantibodies, and jointly filed a patent application for this technology. In the same month, we also concluded a joint research agreement with Kyushu University, a national university corporation, aimed at commercializing a regenerative medicine product for the treatment of chronic heart failure.」

「In the same month, we concluded a joint research agreement with the National Cancer Center, a National Research and Development Agency, aimed at commercializing a new cancer immunotherapy related to Heat Shock Protein105 (HSP105), one of the cancer antigen proteins. In November 2019, we concluded a joint research agreement with Kyoto Prefectural University of Medicine, a public university corporation of Kyoto Prefecture, aimed at commercializing a specific B-cell depletion method using immune cells genetically modified with a new chimeric receptor, called a B-cell antibody receptor (BAR), for diseases caused by the production of autoantibodies, and jointly filed a patent application for this technology. In the same month, we also concluded a joint research agreement with Kyushu University, a national university corporation, aimed at commercializing a regenerative medicine product for the treatment of chronic heart failure.」

「2018年12月には、株式会社JUNTEN BIOと同社が学校法人順天堂と共同で開発を行っている臓器移植後の拒絶反応の抑制を目的とした再生医療等製品の製造技術の開発委受託契約を締結いたしました。」

「2018年12月には、株式会社JUNTEN BIOと同社が学校法人順天堂と共同で開発を行っている臓器移植後の拒絶反応の抑制を目的とした再生医療等製品の製造技術の開発委受託契約を締結いたしました。」

「In the regenerative medicine products business, we aim to commercialize regenerative medicine products through ongoing joint research with university hospitals and other institutions. We are also monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring their pipelines.」

「In the regenerative medicine products business, we aim to commercialize regenerative medicine products through ongoing joint research with university hospitals and other institutions. We are also monitoring development trends for regenerative medicine products in Japan and overseas and undertaking activities with a view to acquiring their pipelines.」

「In addition, as in the previous consolidated fiscal year, our Group is promoting clinical research activities through joint research with university hospitals and core medical institutions in each region, centered on the medical institutions under contract with our Group, with the aim of building evidence for immune cell therapy.」

「In addition, in the cell therapy products business, we are preparing to obtain marketing approval at an early stage for cell therapy products, a type of regenerative medicine product, by using the conditional and time-limited approval system.」

「In the cell therapy products business, we are preparing to obtain marketing approval at an early stage for cell therapy products, a type of regenerative medicine product, by using the conditional and time-limited approval system.」

「As part of our R&D activities, we are working to obtain marketing approval for cell therapy products by promoting development through joint research with university hospitals and other institutions, as well as exploring promising product candidates in Japan and overseas.」

「In the cell therapy products business, we are exploring the potential of cell therapy products through the results of the Group’s research and development activities and through ongoing joint research with university hospitals and other institutions.」